An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy To investigate if multiple intravenous injections of Alpharadin have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocri...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Algeta ALSYMPCA : Essai de phase 3 randomisé évaluant l'efficacité et la tolérance de l'alpharadin, chez des patients ayant un cancer de la prostate. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A double-blind, randomised, multiple dose, phase III, multicentre study of alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.

• Pays France
• Organes Prostate, Os, Métastases osseuses
• Spécialités Thérapies Ciblées

A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases To compare the proportion of patients with PSA response (PSA decrease of 50% from baseline, confirmed three weeks later) of three different repeat dose regimens of Alpharadin in patients with hormone ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients The primary objective of this study is to investigate whether there is a dose-response relationship for radium-223 in patients with painful bone metastases secondary to prostate carcinoma regarding th...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune